200mg Label
Xifaxan Tablet
Product Images NDC 65649-301
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 65649-301). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Salix Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
550mg Label
Not available.*
Chemical Structure (Image 01)
Figure 1 (Image 02)
This appears to be a graph representing the proportion of patients without breakthrough HE versus the days post-randomization, with XIFAXAN as the treatment being evaluated. The hazard ratio, 95% CI, and log-rank p-value are also listed.*
Figure 2 (Image 03)
The text provides information regarding the proportion of patients who did not require hospitalization due to HE-related issues. The data is presented in a graph format with different values for each treatment group. The hazard ratio, confidence interval, and log-rank p-value are also reported. The information appears to be related to a clinical trial or study, but without additional context or further information, it is not possible to provide a more specific description.*
Figure-3 (Image 04)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
